Oliver Bähr
About
Oliver Bähr is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Oliver Bähr has authored 65 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Genetics, 22 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Oliver Bähr's work include Glioma Diagnosis and Treatment (46 papers), Brain Metastases and Treatment (13 papers) and Advanced MRI Techniques and Applications (12 papers). Oliver Bähr is often cited by papers focused on Glioma Diagnosis and Treatment (46 papers), Brain Metastases and Treatment (13 papers) and Advanced MRI Techniques and Applications (12 papers). Oliver Bähr collaborates with scholars based in Germany, Switzerland and United States. Oliver Bähr's co-authors include Elke Hattingen, Joachim P. Steinbach, Michael Weller, Johannes Rieger, Patrick N. Harter, Kea Franz, Patrick Roth, Surasak Phuphanich, Juan Manuel Sepúlveda-Sánchez and David A. Reardon and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Brain.
In The Last Decade
Oliver Bähr
65 papers receiving 3.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Oliver Bähr Germany | 29 | 1.6k | 1.0k | 875 | 713 | 595 | 65 | 3.3k | ||
| Oliver Schnell Germany | 31 | 2.0k 1.2× | 1.1k 1.0× | 523 0.6× | 637 0.9× | 949 1.6× | 118 | 3.8k | ||
| Adelheid Wöhrer Austria | 31 | 1.8k 1.1× | 988 0.9× | 831 0.9× | 542 0.8× | 372 0.6× | 79 | 3.7k | ||
| Helen Wheeler Australia | 27 | 1.4k 0.8× | 849 0.8× | 671 0.8× | 574 0.8× | 331 0.6× | 110 | 2.6k | ||
| Juan Manuel Sepúlveda-Sánchez Spain | 29 | 1.7k 1.0× | 1.2k 1.2× | 1.5k 1.7× | 637 0.9× | 402 0.7× | 181 | 3.9k | ||
| Patrick N. Harter Germany | 38 | 1.5k 0.9× | 1.9k 1.8× | 1.2k 1.4× | 971 1.4× | 327 0.5× | 181 | 4.8k | ||
| Melike Pekmezci United States | 28 | 1.4k 0.8× | 1.3k 1.3× | 514 0.6× | 836 1.2× | 678 1.1× | 101 | 4.0k | ||
| Frits Thorsen Norway | 36 | 1.2k 0.7× | 1.6k 1.6× | 955 1.1× | 972 1.4× | 320 0.5× | 84 | 4.0k | ||
| Oliver Heese Germany | 23 | 1.4k 0.8× | 1.0k 1.0× | 467 0.5× | 640 0.9× | 448 0.8× | 63 | 3.0k | ||
| Joon H. Uhm United States | 37 | 2.1k 1.3× | 1.7k 1.6× | 907 1.0× | 1.1k 1.6× | 425 0.7× | 127 | 4.4k | ||
| Robert Soriano United States | 19 | 1.8k 1.1× | 2.7k 2.6× | 1.5k 1.8× | 1.5k 2.0× | 305 0.5× | 20 | 5.1k |
Countries citing papers authored by Oliver Bähr
Since
Specialization
Citations
This map shows the geographic impact of Oliver Bähr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Bähr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Bähr more than expected).
Fields of papers citing papers by Oliver Bähr
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Oliver Bähr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Bähr. The network helps show where Oliver Bähr may publish in the future.
Co-authorship network of co-authors of Oliver Bähr
This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Bähr. A scholar is included among the top collaborators of Oliver Bähr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Bähr. Oliver Bähr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bähr, Oliver, Ghazaleh Tabatabai, Rainer Fietkau, Roland Goldbrunner, & Martin Glas. (2024). Tumor treating fields (TTFields) therapy in patients with glioblastoma: Long-term survival results from TTFields in Germany in routine clinical care (TIGER) study.. Journal of Clinical Oncology. 42(16_suppl). 2036–2036.
2.
Gramatzki, Dorothee, Jörg Felsberg, Bettina Hentschel, et al.. (2021). Chemotherapy for adult patients with spinal cord gliomas. Neuro-Oncology Practice. 8(4). 475–484.
3.
Steidl, Eike, Marlies Wagner, Katharina Filipski, et al.. (2021). Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. Oncology. 99(4). 215–224.
4.
Wenger, Katharina J., Joachim P. Steinbach, Oliver Bähr, Ulrich Pilatus, & Elke Hattingen. (2020). Lower Lactate Levels and Lower Intracellular pH in Patients with IDH-Mutant versus Wild-Type Gliomas. American Journal of Neuroradiology. 41(8). 1414–1422.
5.
Zeiner, Pia S., Martina Kinzig, Gabriele D. Maurer, et al.. (2019). Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. Journal of Clinical Medicine. 8(12). 2031–2031.
6.
Wick, Wolfgang, Ghazaleh Tabatabai, Martin Schüler, et al.. (2019). Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours. Annals of Oncology. 30. v170–v171.
7.
Wenger, Katharina J., Elke Hattingen, Patrick N. Harter, et al.. (2018). Fitting algorithms and baseline correction influence the results of non‐invasive in vivo quantitation of 2‐hydroxyglutarate with 1H‐MRS. NMR in Biomedicine. 32(1). e4027–e4027.
8.
Wenger, Katharina J., Elke Hattingen, Kea Franz, et al.. (2017). In vivo Metabolic Profiles as Determined by 31P and short TE 1H MR-Spectroscopy. Clinical Neuroradiology. 29(1). 27–36.
9.
Burger, Michael C., Iris Mildenberger, Marlies Wagner, et al.. (2017). Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern. International Journal of Molecular Sciences. 18(4). 726–726.
10.
Wenger, Katharina J., Marlies Wagner, Se-Jong You, et al.. (2017). Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncology Letters. 14(1). 1141–1146.
11.
Steidl, Eike, Ulrich Pilatus, Elke Hattingen, et al.. (2016). Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study. PLoS ONE. 11(12). e0168113–e0168113.
12.
Braczynski, Anne K., Florian Geßler, Saskia Biskup, et al.. (2015). Comprehensive diagnostics in a case of hereditary diffuse leukodystrophy with spheroids. BMC Neurology. 15(1). 103–103.
13.
Herrlinger, Ulrich, David Jones, Martin Glas, et al.. (2015). Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica. 131(2). 309–319.
14.
Baumgarten, Peter, Anna‐Eva Blank, Kea Franz, et al.. (2015). Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro-Oncology. 18(2). 173–183.
15.
Weise, Lutz, Patrick N. Harter, Anne K. Braczynski, et al.. (2014). Confounding Factors in Diagnostics of <b><i>MGMT</i></b> Promoter Methylation Status in Glioblastomas in Stereotactic Biopsies. Stereotactic and Functional Neurosurgery. 92(3). 129–139.
16.
Hattingen, Elke, Alina Jurcoane, Ulrich Pilatus, et al.. (2013). Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival. Neuro-Oncology. 15(10). 1395–1404.
17.
Bähr, Oliver, Mirjam Hermisson, Sabine Rona, et al.. (2011). Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. Acta Neurochirurgica. 154(2). 229–235.
18.
Bähr, Oliver, Elke Hattingen, Johannes Rieger, & Joachim P. Steinbach. (2011). Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro-Oncology. 13(9). 1020–1029.
19.
Maurer, Gabriele D., Daniel P. Brucker, Oliver Bähr, et al.. (2011). Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 11(1). 315–315.
20.
Bähr, Oliver, Johannes Streffer, Stephan Winter, et al.. (1999). Selective Potentiation of Drug Cytotoxicity by NSAID in Human Glioma Cells: The Role of COX-1 and MRP. Biochemical and Biophysical Research Communications. 259(3). 600–605.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Oliver Schnell Breakdown of academic impact, for papers by Adelheid Wöhrer Breakdown of academic impact, for papers by Helen Wheeler Breakdown of academic impact, for papers by Juan Manuel Sepúlveda-Sánchez Breakdown of academic impact, for papers by Patrick N. Harter Breakdown of academic impact, for papers by Melike Pekmezci Breakdown of academic impact, for papers by Frits Thorsen Breakdown of academic impact, for papers by Oliver Heese Breakdown of academic impact, for papers by Joon H. Uhm Breakdown of academic impact, for papers by Robert Soriano